GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bioage Labs Inc (NAS:BIOA) » Definitions » Debt-to-Asset

BIOA (Bioage Labs) Debt-to-Asset : 0.03 (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Bioage Labs Debt-to-Asset?

Bioage Labs's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $6.27 Mil. Bioage Labs's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $3.94 Mil. Bioage Labs's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was $337.38 Mil. Bioage Labs's debt to asset for the quarter that ended in Sep. 2024 was 0.03.

Bioage Labs Debt-to-Asset Historical Data

The historical data trend for Bioage Labs's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioage Labs Debt-to-Asset Chart

Bioage Labs Annual Data
Trend Dec22 Dec23
Debt-to-Asset
0.09 2.05

Bioage Labs Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Asset Get a 7-Day Free Trial - 2.05 0.07 0.07 0.03

Competitive Comparison of Bioage Labs's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Bioage Labs's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bioage Labs's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bioage Labs's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Bioage Labs's Debt-to-Asset falls into.


Bioage Labs Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Bioage Labs's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(45.051 + 8.201) / 25.924
=2.05

Bioage Labs's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(6.273 + 3.94) / 337.381
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioage Labs  (NAS:BIOA) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Bioage Labs Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Bioage Labs's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Bioage Labs Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bioage Labs Inc (NAS:BIOA) » Definitions » Debt-to-Asset
Comparable Companies
Traded in Other Exchanges
N/A
Address
1445A South 50th Street, Richmond, CA, USA, 94804
Website
https://www.bioagelabs.com
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. Its Products are Azelaprag (BGE-105), an apelin receptor APJ agonist that increases weight loss and improves body composition combined with incretin drugs. and BGE-100 is targeting metabolic diseases and neuroinflammation.